STOCK TITAN

[SCHEDULE 13G] Organogenesis Holdings Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Organogenesis Holdings, Inc. Schedule 13G shows First Light Asset Management, LLC and Mathew P. Arens report joint beneficial ownership of common stock. The Manager is reported to beneficially own 8,061,404 shares (representing 6.35% of the class) while Mr. Arens is reported to beneficially own 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. The filing is made under Rule 13d-1(b) and includes a joint filing agreement.

Organogenesis Holdings, Inc. – Nel Schedule 13G viene indicato che First Light Asset Management, LLC e Mathew P. Arens dichiarano una titolarità beneficiaria congiunta delle azioni ordinarie. Il Manager detiene beneficiariamente 8.061.404 azioni (pari al 6,35% della classe), mentre il Sig. Arens detiene beneficiariamente 8.309.404 azioni (il 6,55%), comprese 231.000 azioni detenute direttamente con pieno diritto di voto e di disposizione. L’invio è effettuato ai sensi della Rule 13d-1(b) e comprende un accordo di deposito congiunto.

Organogenesis Holdings, Inc. – En el Schedule 13G se informa que First Light Asset Management, LLC y Mathew P. Arens declaran propiedad beneficiaria conjunta de acciones ordinarias. El gestor posee beneficiariamente 8.061.404 acciones (representando el 6,35% de la clase), mientras que el Sr. Arens posee beneficiariamente 8.309.404 acciones (6,55%), incluidas 231.000 acciones mantenidas directamente con pleno derecho de voto y de disposición. La presentación se realiza conforme a la Rule 13d-1(b) e incluye un acuerdo de presentación conjunta.

Organogenesis Holdings, Inc. – Schedule 13G에 따르면 First Light Asset Management, LLC와 Mathew P. Arens는 보통주에 대한 공동 실소유권을 신고했습니다. 매니저는 8,061,404주를 실소유하고 있는 것으로 보고되었으며(해당 종목의 6.35%), Arens 씨는 8,309,404주(6.55%)를 실소유하고 있으며 그중 231,000주는 단독 의결권 및 처분권을 가진 직접 보유입니다. 이 제출은 Rule 13d-1(b)에 따라 이루어졌으며 공동 제출 계약이 포함되어 있습니다.

Organogenesis Holdings, Inc. – Le Schedule 13G indique que First Light Asset Management, LLC et Mathew P. Arens déclarent une propriété bénéficiaire conjointe des actions ordinaires. Le gestionnaire détient bénéficiairement 8 061 404 actions (représentant 6,35% de la catégorie), tandis que M. Arens détient bénéficiairement 8 309 404 actions (6,55%), dont 231 000 actions détenues directement avec seul pouvoir de vote et de disposition. Le dépôt est effectué en vertu de la Rule 13d-1(b) et inclut un accord de dépôt conjoint.

Organogenesis Holdings, Inc. – Im Schedule 13G wird angegeben, dass First Light Asset Management, LLC und Mathew P. Arens gemeinschaftliches wirtschaftliches Eigentum an Stammaktien melden. Der Manager wird mit wirtschaftlichem Eigentum an 8.061.404 Aktien (entsprechend 6,35% der Klasse) angegeben, während Herr Arens mit 8.309.404 Aktien (6,55%) ausgewiesen wird, darunter 231.000 Aktien, die direkt mit alleinigem Stimm- und Verfügungsrecht gehalten werden. Die Einreichung erfolgt gemäß Rule 13d-1(b) und enthält eine gemeinsame Einreichungsvereinbarung.

Positive
  • Disclosure of material stake: First Light reports 8,061,404 shares (6.35%) and Mr. Arens reports 8,309,404 shares (6.55%), both above 5% thresholds.
  • Clear allocation of voting/dispositive power: Filing specifies sole versus shared voting and disposition (231,000 shares sole by Mr. Arens; shared power for larger holdings).
  • Filed under Rule 13d-1(b): Certification states holdings are in the ordinary course of business and not for the purpose of changing control.
Negative
  • None.

Insights

TL;DR Joint disclosure shows institutional adviser and CEO-level individual each above 5% ownership, a notable ownership concentration.

The filing discloses that First Light Asset Management holds 8,061,404 shares (6.35%) via managed accounts and private funds while Mathew P. Arens, as managing member, is reported with 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. This is a Schedule 13G filed under Rule 13d-1(b), indicating passive investment intent per the certification. The positions disclosed are sufficiently large to be material to holders' ownership profiles but the filing explicitly states shares are held in the ordinary course of business and not to influence control.

TL;DR Disclosure clarifies allocation of voting and dispositive power between the adviser and its principal, aiding governance transparency.

The Schedule 13G clarifies that shared voting and dispositive power of 8,061,404 shares is exercised by First Light as adviser, while Mr. Arens reports both shared control (8,078,404 shares) and sole control over 231,000 shares. The joint filing and certification language indicate a passive posture under Rule 13d-1(b). For governance, the filing documents an identifiable concentrated stake and differentiates sole versus shared authorities, which is important for board and shareholder oversight but does not assert any change in control intentions.

Organogenesis Holdings, Inc. – Nel Schedule 13G viene indicato che First Light Asset Management, LLC e Mathew P. Arens dichiarano una titolarità beneficiaria congiunta delle azioni ordinarie. Il Manager detiene beneficiariamente 8.061.404 azioni (pari al 6,35% della classe), mentre il Sig. Arens detiene beneficiariamente 8.309.404 azioni (il 6,55%), comprese 231.000 azioni detenute direttamente con pieno diritto di voto e di disposizione. L’invio è effettuato ai sensi della Rule 13d-1(b) e comprende un accordo di deposito congiunto.

Organogenesis Holdings, Inc. – En el Schedule 13G se informa que First Light Asset Management, LLC y Mathew P. Arens declaran propiedad beneficiaria conjunta de acciones ordinarias. El gestor posee beneficiariamente 8.061.404 acciones (representando el 6,35% de la clase), mientras que el Sr. Arens posee beneficiariamente 8.309.404 acciones (6,55%), incluidas 231.000 acciones mantenidas directamente con pleno derecho de voto y de disposición. La presentación se realiza conforme a la Rule 13d-1(b) e incluye un acuerdo de presentación conjunta.

Organogenesis Holdings, Inc. – Schedule 13G에 따르면 First Light Asset Management, LLC와 Mathew P. Arens는 보통주에 대한 공동 실소유권을 신고했습니다. 매니저는 8,061,404주를 실소유하고 있는 것으로 보고되었으며(해당 종목의 6.35%), Arens 씨는 8,309,404주(6.55%)를 실소유하고 있으며 그중 231,000주는 단독 의결권 및 처분권을 가진 직접 보유입니다. 이 제출은 Rule 13d-1(b)에 따라 이루어졌으며 공동 제출 계약이 포함되어 있습니다.

Organogenesis Holdings, Inc. – Le Schedule 13G indique que First Light Asset Management, LLC et Mathew P. Arens déclarent une propriété bénéficiaire conjointe des actions ordinaires. Le gestionnaire détient bénéficiairement 8 061 404 actions (représentant 6,35% de la catégorie), tandis que M. Arens détient bénéficiairement 8 309 404 actions (6,55%), dont 231 000 actions détenues directement avec seul pouvoir de vote et de disposition. Le dépôt est effectué en vertu de la Rule 13d-1(b) et inclut un accord de dépôt conjoint.

Organogenesis Holdings, Inc. – Im Schedule 13G wird angegeben, dass First Light Asset Management, LLC und Mathew P. Arens gemeinschaftliches wirtschaftliches Eigentum an Stammaktien melden. Der Manager wird mit wirtschaftlichem Eigentum an 8.061.404 Aktien (entsprechend 6,35% der Klasse) angegeben, während Herr Arens mit 8.309.404 Aktien (6,55%) ausgewiesen wird, darunter 231.000 Aktien, die direkt mit alleinigem Stimm- und Verfügungsrecht gehalten werden. Die Einreichung erfolgt gemäß Rule 13d-1(b) und enthält eine gemeinsame Einreichungsvereinbarung.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



First Light Asset Management, LLC
Signature:/s/ Kurt T. Peterson
Name/Title:Kurt T. Peterson/Chief Compliance Officer
Date:08/14/2025
Mathew P. Arens
Signature:/s/ Mathew P. Arens
Name/Title:Mathew P. Arens/Chief Executive Officer
Date:08/14/2025
Exhibit Information

Exhibit A: Joint Filing Agreement

FAQ

How many Organogenesis (ORGO) shares does First Light Asset Management report owning?

First Light Asset Management reports beneficial ownership of 8,061,404 shares, representing 6.35% of the class.

What is Mathew P. Arens' reported ownership in ORGO?

Mathew P. Arens reports beneficial ownership of 8,309,404 shares, representing 6.55%, including 231,000 shares with sole voting and dispositive power.

Under what rule was this Schedule 13G filed?

The Schedule 13G was filed pursuant to Rule 13d-1(b), indicating a passive reporting category.

Does the filing state the shares are intended to influence control of ORGO?

No. The certification states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Where are the reporting persons' principal offices located?

The reporting persons' principal business office is listed as 3300 Edinborough Way, Suite 201, Edina, MN 55435.
Organogenesis Hldgs Inc

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Latest SEC Filings

ORGO Stock Data

622.87M
67.69M
46.49%
54.06%
7.67%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CANTON